"Captoril"@en . . "Acepress"@en . "Captoprilum"@en . . . "60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)"@en . . . . "Hypertil"@en . . "62571-86-2"@en . . "There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Captopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Captopril\u2019s affinity for ACE is approximately 30,000 times greater than that of ATI."@en . . . . . . . . . . . . . . . . . . " "@en . . . . . . . "Captopryl"@en . . . "Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia. "@en . "approved"@en . "25-30% bound to plasma proteins, primarily albumin"@en . . "Apopril"@en . . . . . . . . . . . "Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. "@en . . . . . . . "Lopirin"@en . "Food decreases absorption by 25 - 40%. Clinical significance is debatable. "@en . . . "# Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/90928 # Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6253826 # Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12724335"@en . . . "Humans and other mammals"@en . . "Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension. "@en . . "Symptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema."@en . . . . . . . . . . . "Charles M. Zepp, \"Methods for preparing captopril and its analogues.\" U.S. Patent US5166361, issued July, 1981."@en . . . . . . . . . . . . . . . . . "D-2-Methyl-3-mercaptopropanoyl-L-proline"@en . . . . . . . . . . . "2 hours"@en . . . . . . . . . "(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid"@en . . . . . . . . . . . . . . . . . . . . . . . "CP"@en . "Dilabar"@en . . "Garranil"@en . . . "Tenosbon"@en . . "High salt intake may attenuate the antihypertensive effect of captopril. "@en . . . . "L-Captopril"@en . . "Tensoprel"@en . . . "Cesplon"@en . . "D-3-Mercapto-2-methylpropanoyl-L-proline"@en . . . "Tensobon"@en . . . "Captolane"@en . . . "For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy. "@en . . "Captopril"@en . "Capoten"@en .